Barclays PLC Castle Biosciences Inc Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Castle Biosciences Inc stock. As of the latest transaction made, Barclays PLC holds 52,301 shares of CSTL stock, worth $1.44 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

52,301

Previous 52,301 -0.0%

Holding current value

$1.44 Million

Previous $1.49 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$17.4 - $31.47 $688,465 - $1.25 Million	39,567 Added 310.72%	52,301 $1.49 Million
Q2 2024 Aug 14, 2024	SELL	$18.84 - $24.94 $653,578 - $865,193	-34,691 Reduced 73.15%	12,734 $277,000
Q1 2024 May 15, 2024	BUY	$18.06 - $25.3 $145,292 - $203,538	8,045 Added 20.43%	47,425 $1.05 Million
Q4 2023 Feb 15, 2024	BUY	$12.19 - $22.43 $370,551 - $681,827	30,398 Added 338.43%	39,380 $850,000
Q3 2023 Nov 07, 2023	SELL	$13.28 - $20.3 $7,011 - $10,718	-528 Reduced 5.55%	8,982 $151,000
Q2 2023 Aug 03, 2023	SELL	$11.66 - $26.0 $34,327 - $76,544	-2,944 Reduced 23.64%	9,510 $131,000
Q1 2023 May 04, 2023	BUY	$19.47 - $28.49 $114,211 - $167,122	5,866 Added 89.04%	12,454 $282,000
Q4 2022 Feb 13, 2023	SELL	$18.08 - $30.0 $337,119 - $559,380	-18,646 Reduced 73.89%	6,588 $155,000
Q3 2022 Nov 03, 2022	BUY	$22.51 - $34.32 $541,140 - $825,052	24,040 Added 2013.4%	25,234 $658,000
Q2 2022 Aug 12, 2022	SELL	$16.0 - $45.99 $37,744 - $108,490	-2,359 Reduced 66.39%	1,194 $26,000
Q1 2022 May 16, 2022	BUY	$33.17 - $46.98 $117,853 - $166,919	3,553 New	3,553 $159,000

Others Institutions Holding CSTL

# of Institutions

201

Shares Held

24.5M

Call Options Held

303K

Put Options Held

30.3K

View Full List

About CASTLE BIOSCIENCES INC

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $724M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

More about CSTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account